WIG20

Ryvu Therapeutics Reports 2023 Half-Year Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, September 13, 2023
Good manufacturing practice, Incentive program, WSE, Congress, QP, Patient, United States Commercial Service, SE, Disease, Warsaw Stock Exchange, Research, USD, European Hematology Association, International Conference on Afghanistan, London (2010), CGMP, Hematology, ADC, Phase, Conference, Venetoclax, Safety, BioNTech, WIG20, Exelixis, API, History, Fibrosis, Pancreatic serous cystadenoma, Contract research organization, MA, Therapy, Splenomegaly, Cost, EDC, Data management, Good, ABM, AML, EHA, Dietary supplement, Pharmaceutical industry, Cryptocurrency

Updated clinical and preclinical data on RVU120 were presented at the European Hematology Associated (EHA) Congress in June 2023.

Key Points: 
  • Updated clinical and preclinical data on RVU120 were presented at the European Hematology Associated (EHA) Congress in June 2023.
  • $14M in non-dilutive grant funding was secured from the Medical Research Agency (ABM) – the largest grant obtained to date by Ryvu.
  • KRAKOW, Poland, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, reported today financial results for the first half of 2023 and provided a corporate update.
  • “The last months of 2023 were a productive period for Ryvu as we made significant developments across our clinical programs, collaboration activity, and strengthening our balance sheet”, said Pawel Przewiezlikowski, CEO of Ryvu Therapeutics.

Ryvu Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, May 16, 2023
SDMA, MTAP, Incentive program, WSE, Congress, EIB, Myeloproliferative neoplasm, Warsaw Stock Exchange, Service, MTA, Culture, Research, WT, Growth, Phase, Conference, Safety, Common, BioNTech, WIG20, 100 Best Companies to Work For, Pancreatic serous cystadenoma, Publication, SWIG, CEE, Therapy, PRMT5, European Hematology Association, Exelixis, Good clinical data management practice, MDS, AML, EHA, Pharmaceutical industry, Vaccine, Cryptocurrency, Patient

These molecules can selectively inhibit the growth of MTAP-deleted cancer cells in prolonged 3D culture, which correlates with the inhibition of PRMT5-dependent protein symmetric dimethylation (SDMA).

Key Points: 
  • These molecules can selectively inhibit the growth of MTAP-deleted cancer cells in prolonged 3D culture, which correlates with the inhibition of PRMT5-dependent protein symmetric dimethylation (SDMA).
  • Ryvu was also the winner in three other categories: “Investor Relations”, “Development Perspectives”, and “Products and Services Innovation”.
  • Initiation of Phase 2 trials of RVU120 in solid tumors and AML/HR-MDS is expected in 2H 2023.
  • As of May 11, 2023, Ryvu Therapeutics held $71.8M in cash, cash equivalents and bonds.

Ryvu Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Friday, March 24, 2023
SDMA, MTAP, Incentive program, WSE, Patient, PIM, MM, EIB, Leukemia, Therapy, Warsaw Stock Exchange, Service, MTA, Culture, DLBCL, Multiple myeloma, Research, WT, Hematology, Growth, European Investment Bank, Phase, Common, BioNTech, WIG20, AACR, BofA Securities, Cancer, IC50, 100 Best Companies to Work For, Acute myeloid leukemia, American Association for Cancer Research, Publication, Germinal center B-cell like diffuse large B-cell lymphoma, SWIG, HL, Update, PRMT5, Partnership, Exelixis, AML, Pharmaceutical industry, Vaccine, Medical imaging

“2022 was a highly productive year for Ryvu as we made significant strides across our clinical programs, collaboration activity, and in strengthening our balance sheet,” said Pawel Przewiezlikowski, co-founder, largest shareholder and CEO of Ryvu Therapeutics.

Key Points: 
  • “2022 was a highly productive year for Ryvu as we made significant strides across our clinical programs, collaboration activity, and in strengthening our balance sheet,” said Pawel Przewiezlikowski, co-founder, largest shareholder and CEO of Ryvu Therapeutics.
  • Among the investors participating in this offering were also company insiders (including the CEO) with a total investment of over $5M in the offering.
  • Cash Position – On December 31, 2022, Ryvu Therapeutics held $23.2M in cash and cash equivalents, compared to $20.5M at the end of 2021.
  • Net Loss Attributable to Common Shareholders – Net loss attributable to common shareholders excluding the non-cash cost of valuation of the Incentive Program was $1.4M, for the fourth quarter of 2022, compared to the $2.6M, for the fourth quarter of 2021.

SecBI to Support Orange Polska in Augmenting Its Managed Cyber Services

Retrieved on: 
Wednesday, May 2, 2018
Warsaw Stock Exchange, WIG20, Orange S.A., Partner Communications Company, Economy of Europe, Economy of France, Stock market

"This partnership is aimed at enhancing our current portfolio of cybersecurity services, particularly in SOC-as-a-Service, breach response, triaging, and hunting," said Tomasz Matua, Director of ICT Infrastructure and Cybersecurity at Orange Polska.

Key Points: 
  • "This partnership is aimed at enhancing our current portfolio of cybersecurity services, particularly in SOC-as-a-Service, breach response, triaging, and hunting," said Tomasz Matua, Director of ICT Infrastructure and Cybersecurity at Orange Polska.
  • Orange Polska is a unique convergent operator in the Polish market, providing mobile and fixed-line telco services, as well as TV and value-added services such as energy and banking.
  • Orange Polska is a part of Orange Group, one of the biggest worldwide telecom operators.
  • Orange Polska shares are listed on the Warsaw Stock Exchange (symbol OPL) and are included in WIG20 index.